Complement 3d: From molecular adjuvant to target of immune escape mechanisms

Clinical Immunology

Volumn 121, Issue 2, 2006, Pages 177-185

  Bergmann Leitner, Elke S ^a   Leitner, Wolfgang W ^b   Tsokos, George C ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adjuvant; B lymphocyte; Complement; DNA vaccine; Immune escape

Indexed keywords

BOVINE VIRAL DIARRHEA VIRUS VACCINE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3D; COMPLEMENT RECEPTOR; DIPHTHERIA VACCINE; DNA VACCINE; HERPES VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MALARIA VACCINE; MEASLES VACCINE; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; B LYMPHOCYTE ACTIVATION; BACTERIAL INFECTION; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CROSS LINKING; DRUG EFFICACY; HOST CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; MOLECULAR MECHANICS; MYCOSIS; NONHUMAN; OPSONIZATION; PARASITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TUMOR GROWTH; VACCINATION; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; COMPLEMENT ACTIVATION; COMPLEMENT C3D; COMPLEMENT SYSTEM PROTEINS; HUMANS; MODELS, IMMUNOLOGICAL; TUMOR ESCAPE; VACCINES, DNA;

EID: 33750002738     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.07.001     Document Type: Review

References (83)

1. Janeway C.A., and Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20 (2002) 197-216
2. In: Paul W.E. (Ed). Fundamental Immunology (2003), Lippinscott Williams and Wilkins, Philadelphia
3. Fearon D.T., and Carroll M.C. Regulation of B lymphocytes responses to foreign and self-antigens by the CD19/CD21 complex. Annu. Rev. Immunol. 18 (2000) 393-422
4. Sohn J.-H., Bora P.S., Suk H.-J., Molina H., Kaplan H.J., and Bora N.S. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat. Med. 9 (2003) 206-212
5. Petty H.R., Worth R.G., and Todd R.R. Interactions of integrins with their partner proteins in leukocyte membranes. Immunol. Res. 25 (2002) 75-95
6. Erdei A., Prechl J., Isaak A., and Molnar E. Regulation of B-cell activation by complement receptors CD21 and CD35. Curr. Pharm. Des. 9 (2003) 1849-1860
7. Kinoshita T., Thyphronitis G., Tsokos G.C., Finkelman F.D., Hong K., Sakai H., and Inoue K. Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor. Int. Immunol. 2 (1990) 651
8. Tolnay M., and Tsokos G.C. Complement receptor 2 in the regulation of the immune response. Clin. Immunol. Immunopathol. 88 (1998) 123-132
9. Tsokos G.C., Lambris J.D., Finkelman F.D., Anastassiou E.D., and June C.H. Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration. J. Immunol. 144 (1990) 1640-1645
10. Thornton B.P., Vetvicka V., and Ross G.D. Function of C3 in a humoral response: iC3b/C3dg bound to an immune complex generated with natural antibody and a primary antigen promotes antigen uptake and the expression of co-stimulatory molecules by all B cells, but only stimulates immunoglobulin synthesis by antigen-specific B cells. Clin. Exp. Immunol. 104 (1996) 531-537
11. Kozono Y., Abe R., Kozono H., Kelly R.G., Azuma T., and Holers V.M. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J. Immunol. 160 (1998) 1565-1572
12. Goeckeritz B.E., Lees A., Vos O., Tsokos G.C., Kuhlbusch K., and Mond J.J. Enhanced and sustained activation of human B cells by anti-immunoglobulin conjugated to the EBV glycoprotein gp350. Eur. J. Immunol. 30 (2000) 969-973
13. Mongini P.K.A., Vilenski M.A., Highet P., and Inman J.K. The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon coligation of the antigen receptor with CD21(CR2). J. Immunol. 159 (1997) 3782
14. Carter R.H., and Fearon D.T. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256 (1992) 105-107
15. Fischer M.B., Ma M., Goerg S., Zhou X., Xia J., Finco O., Han S., Kelsoe G., Howard R.G., Rothstein T.L., Kremmer E., Rosen F.S., and Carroll M.C. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J. Immunol. 157 (1996) 549-556
16. Ahearn J.M., Fischer M.B., Croix D., Goerg S., Ma M., Xia J., Zhou X., Howard R.G., Rothstein T.L., and Carroll M.C. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 4 (1996) 251-262
17. Molina H., Holers V.M., Li B., Fung Y., Mariathasan S., Goellner J., Strauss-Schoenberger J., Karr R.W., and Chaplin D.D. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 3357-3361
18. Cherukuri A., Cheng P.C., and Pierce S.K. The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J. Immunol. 167 (2001) 163-172
19. Thornton B.P., Vetvicka V., and Ross G.D. Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. J. Immunol. 152 (1994) 1727
20. Test S.T., Mitsuyoshi J., Connolly C.C., and Lucas A.H. Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharides. Infect. Immun. 69 (2001) 3031-3040
21. Reynes M., Aubert J.P., Cohen J.H., Audouin J., Tricottet V., Diebold J., and Kazatchkine M.D. Human follicular dendritic cells express CR1, CR2 and CR3 complement receptor antigens. J. Immunol. 135 (1985) 2687-2694
22. Nielsen C.H., Fischer E.M., and Leslie G.Q. The role of complement in the acquired immune response. Immunol. 100 (2000) 4-12
23. Lindhout E., Mevissen M.L., Kwekkeboom J., Tager J.M., and De Grout C. Direct evidence that human follicular dendritic cells (FDC) rescue germinal centre B cells from death by apoptosis. Clin. Exp. Immunol. 91 (1993) 330
24. Qin D., Wu J., Carroll M.C., Burton G.F., Szakal A., and Tew J.G. Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses. J. Immunol. 161 (1998) 4549-4554
25. Chen Z., Koralov S.B., Gendelman M., Carroll M.C., and Kelsoe G. Humoral immune responses in Cr2-/- mice: enhanced affinity maturation but impaired antibody persistence. J. Immunol. 164 (2000) 4522-4532
26. Zinkernagel R.M., Ehl S., Aichele P., Oehen S., Kundig T., and Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev. 156 (1997) 199-209
27. Haas K.M., Toapanta F.R., Oliver J.A., Poe J.C., Weis J.H., Karp D.R., Bower J.F., Ross T.M., and Tedder T.F. C3d functions as a molecular adjuvant in the absence of CD21/35 expression. J. Immunol. 172 (2004) 5833-5837
28. Kaya Z., Afanasyeva M., Wang Y., Dohmen K.M., Schlichtling J., Tretter T., Fairweather D., Holers V.M., and Rose N.R. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat. Immunol. 2 (2001) 739-745
29. Cutler A.J., Botto M., van Essen D., Rivi R., Davies K.A., Gray D., and Walport M.J. T cell-dependent immune response in C1q-deficient mice: defective interferon gamma production by antigen-specific T cells. J. Exp. Med. 187 (1998) 1789-1797
30. Bergmann-Leitner E.S., Scheiblhofer S., Weiss R., Duncan E.H., Leitner W.W., Chen D., Angov E., Khan F., Williams J.L., Winter D.B., Thalhamer J., Lyon J.A., and Tsokos G.C. C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. Int. Immunol. 17 (2005) 245-255
31. Bennet M., and Leanderson T. Was it there all the time?. Scand. J. Immunol. 57 (2003) 499-505
32. Jozsi M., Prechl J., Bajtay Z., and Erdei A. Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes. J. Immunol. 168 (2002) 2782-2788
33. Marth T., and Kelsall B.L. Regulation of interleukin-12 by complement receptor 2 signaling. J. Exp. Med. 185 (1997) 1987-1995
34. 2+-complexed crystal structures. J. Cell Biol. 143 (1998) 1523-1534
35. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C., and Fearon D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271 (1996) 348-350
36. Green T.D., Newton B.R., Rota P.A., Xu Y., Robinson H.L., and Ross T.M. C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine 20 (2002) 242-248
37. Green T.D., Montefiori D.C., and Ross T.M. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J. Virol. 77 (2003) 2046-2055
38. Mitchell J.A., Green T.D., Bright R.A., and Ross T.M. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 21 (2003) 902-914
39. Ross T.M., Xu Y., Bright R.A., and Robinson H.L. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat. Immunol. 1 (2000) 127-131
40. Ross T.M., Xu Y., Green T.D., Montefiori D.C., and Robinson H.L. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res. Hum. Retrovir. 17 (2001) 829-835
41. Suradhat S., Braun R.P., Lewis P.J., Babiuk L.A., van Drunen Littel-van den Hurk S., Griebel P.J., and Baca-Estrada M.E. Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization. Vet. Immunol. Immunopathol. 83 (2001) 79-92
42. Bower J.F., Yang X., Sodroski J., and Ross T.M. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J. Virol. 78 (2004) 4433-4443
43. Gor D.O., Ding X., Li Q., and Greenspan N.S. Genetic fusion of three tandem copies of murine C3d sequences to diphtheria toxin fragment B elicits a decreased fragment B-specific antibody response. Immunol. Lett. 102 (2006) 38-49
44. Leitner W.W., Seguin M.C., Ballou W.R., Seitz J.P., Schultz A.M., Sheehy M.J., and Lyon J.A. Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J. Immunol. 159 (1997) 6112-6119
45. Weiss R., Scheiblhofer S., Freund J., Ferreira F., Livey I., and Thalhamer J. Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine 20 (2002) 3148-3154
46. Heyman B., Wiersma E.J., and Kinoshita T. In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody. J. Exp. Med. 172 (1990) 665
47. Gustavsson S., Kinoshita T., and Heyman B. Antibodies to murine complement receptor 1 and 2 can inhibit the antibody response in vivo without inhibiting T cell receptor induction. J. Immunol. 154 (1995) 6524-6528
48. Chakravarty L., Zabel M.D., Weiss J.J., and Weiss J.H. Depletion of Lyn kinase from the BCR complex and inhibition of B cell activation by excess CD21 ligation. Int. Immunol. 14 (2002) 139-146
49. Bergmann-Leitner E.S., Duncan E.H., and Leitner W.W. Identification and targeting of tumor escape mechanisms: a new hope for cancer therapy?. Curr. Pharm. Des. 9 (2003) 2009-2023
50. Rozanov D.V., Savinov A.Y., Golubkov V.S., Postnova T.I., Remacle A., Tomlinson S., and Strongin A.Y. Cellular membrane tupe-1 matrix metalloproteinase (MT1-MMP) cleaves C3b, an essential component of the complement system. J. Biol. Chem. 279 (2004) 46551-46557
51. Frade R. Structure and functions of proteases which cleave human C3 and are expressed on normal or tumor human cells: some are involved in tumorigenic and metastatic properties of human melanoma cells. Immunopharmacology 42 (1999) 39-45
52. Varsano S., Rashkovsky L., Shapiro H., Ophir D., and Mark-Bentankur T. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin. Exp. Immunol. 113 (1998) 173-182
53. Caragine T.A., Okada N., Frey A.B., and Tomlinson S. A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. Cancer Res. 62 (2002) 1110-1115
54. Junnikkala S., Jokirantaa T.S., Friese M.A., Jarva H., Zipfel P.F., and Meri S. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J. Immunol. 164 (2000) 6075-6081
55. Huemer H.P., Wang Y., Garred P., Koistinen V., and Oppermann S. Herpes simplex virus glycoprotein C: molecular mimicry of complement regulatory proteins by a viral protein. Immunology 79 (1993) 639-647
56. Matsunami K., Miyagawa S., Fukuta D., and Shirakura R. Regulation of complement-mediated swine endothelial cell lysis by herpes simplex virus glycoprotein, gC1. J. Biochem. (Tokyo) 131 (2002) 745-749
57. Judson K.A., Lubinski J.M., Jiang M., Chang Y., Eisenberg R.J., Cohen G.H., and Friedman H.M. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection. J. Virol. 77 (2003) 12639-12645
58. Sahu A., Isaacs S.N., Soulika A.M., and Lambris J.D. Interaction of vaccinia virus complement control protein with human complement proteins factor 1-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J. Immunol. 160 (1998) 5596-5604
59. Kotwal G.J., Isaacs S.N., McKenzie R., Frank M.M., and Moss B. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250 (1990) 827-830
60. Spiller O.B., Blackbourn D.J., Mark L., Proctor D.G., and Blom A.M. Functional activity of the complement regulator encoded by Kaposi's sarcoma-associated herpesvirus. J. Biol. Chem. 278 (2003) 9283-9289
61. Dopper S., Wiflingseder D., Prodinger W.M., Stiegler G., Speth C., Dierich M.P., and Stoiber H. Mechanism(s) promoting HIV-1 infection of primary unstimulated T lymphocytes in autologous B cell/T cell co-cultures. Eur. J. Immunol. 33 (2003) 2098-2107
62. Bajtay Z., Speth C., Erdei A., and Dierich M.P. Cutting edge: productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18). J. Immunol. 173 (2004) 4775-4778
63. Banki Z., Kacani L., Rusert P., Pruenster M., Wiflingseder D., Falkensammer B., Stellbrink H.J., van Lunzen J., Trkola A., Dierich M.A., and Stoiber H. Complement dependent trapping of infectious HIV in human lymphoid tissues. AIDS 19 (2005) 481-486
64. Munoz E., Vidarte L., Pastor C., Casado M., and Vivanco F. A small domain (6.5 kDa) of bacterial protein G inhibits C3 covalent binding to the Fc region of IgG immune complexes. Eur. J. Immunol. 28 (1998) 2591-2597
65. Mueller-Ortiz S.L., Wanger A.R., and Norris S.J. Mycobacterial protein HbhA binds human complement component C3. Infect. Immun. 69 (2001) 7501-7511
66. Schorey J.S., Carroll M.C., and Brown E.J. A macrophage invasion mechanism by pathogenic mycobacteria. Science 277 (1997) 1091-1093
67. Rooyakkers A.W., and Stokes R.W. Absence of complement receptor 3 results in reduced binding and ingestion of Mycobacterium tuberculosis but has not significant effect on the induction of reactive oxygen an nitrogen intermediates or on the survival of the bacteria in resident and interferon-gamma activated macrophages. Microb. Pathog. 39 (2005) 57-67
68. Puentes S.M., Da Silva R.P., Sacks D., Hammer C.H., and Joiner K.A. Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-C9. J. Immunol. 145 (1990) 4311-4316
69. Sacks D., and Sher A. Evasion of innate immunity by parasitic protozoa. Nat. Immunol. 3 (2002) 1041-1047
70. Raper J., Fung R., Ghiso J., Nussenzweig V., and Tomlinson S. Characterization of a novel trypanosome lytic factor from human serum. Infect. Immun. 67 (1999) 1910-1916
71. Alexander J., and Russel D.G. The interaction of Leishmania species with macrophages. Adv. Parasitol. 31 (1992) 175-254
72. Norris K.A., Bradt B., Cooper N.R., and So M. Characterization of a Trypanosoma cruzi C3 binding protein with unction and genetic similarities to the human complement regulatory protein, decay-accelerating factor. J. Immunol. 147 (1991) 2240-2247
73. Kawamoto Y., Winger L.A., Hong K., Matsuoka H., Chinzei Y., Kawamoto F., Kamimura K., Arakawa R., Sinden R.E., and Miyama A. Plasmodium berghei: sporozoites are sensitive to human serum but not susceptible host serum. Exp. Parasitol. 75 (1992) 361-368
74. Margos G., Navarette S., Butcher G., Davies A., Willers C., Sinden R.E., and Lachmann P.J. Interaction between host complement and mosquito-midgut-stage Plasmodium berghei. Infect. Immun. 69 (2001) 5064-5071
75. Giribaldi G., Ulliers D., Mannu F., Arese P., and Turini F. Growth of Plasmodium falciparum induces stage-dependent haemichrome formation, oxidate aggregation of band 3, membrane deposition of complement and antibodies, and phagocytosis of parasitized erythrocytes. Br. J. Haematol. 113 (2001) 492-499
76. Stanley H.A., Mayes J.T., Cooper N.R., and Reese R.T. Complement activation by the surface of Plasmodium falciparum infected erythrocytes. Mol. Immunol. 21 (1984) 145-150
77. Rowe J.A., Moulds J.M., Newbold C.I., and Miller L.H. P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement receptor-1. Nature 388 (1997) 292-295
78. Kirchgatter K., and Del Portillo H.A. Clinical and molecular aspects of severe malaria. An. Acad. Bras. Cienc. 77 (2005) 455-475
79. Netea M.G., Van der Graaf C., Van der Meer J.W., and Kullberg B.J. Recognition of fungal pathogens by Toll-like receptors. Eur. J. Clin. Microbiol. Infect. Dis. 23 (2004) 672-676
80. Stringaro A., Crateri P., Adriani D., Arancia G., Cassone A., Calderone R.A., and De Bernardis F. Expression of the complement-binding protein (MP60) of Candida albicans in experimental vaginitis. Mycopathologia 144 (1999) 147-152
81. Lopez-Ribot J.L., Martinez J.P., and Chaffin W.L. Comparative study of the C3d receptor and 58-kilodalton fibrinogen-binding mannoproteins of Candida albicans. Infect. Immun. 63 (1995) 2126-2132
82. Chaffin W.L., Lopez-Ribot J.L., Casanova M., Gozalbo D., and Martinez J.P. Cell wall and secreted proteins of Candida albicans: identification, function, and expression. Microbiol. Mol. Biol. Rev. 62 (1998) 130-180
83. Wang L., Sunyer J.O., and Bello L.J. Fusion to C3d enhances the immunogenicity of the E2 glycoprotein of type 2 bovine viral diarrhea virus. J. Virol. 78 (2004) 1616-1622